CD4 and sexually transmitted disease: As in Dybul's clinical trial, our simulations have a treatment period of 48 weeks, enroll patients with similar CD4+ cells counts (CD4+ cells >300 cells/mm3) and test the STI schedule with 8 weeks of treatment and 4 weeks of interruption.